Indegene Ltd (INDGN)
₹589.20
Mkt cap
₹14,440 Cr
P/E ratio
34.70
P/B
4.53
Div yield
0.38%
ROE
14.40%
ROCE
18.80%
EPS (TTM)
₹16.98
Book value
₹130
52W range
424–612
Sector
Healthcare
Price history
Previous close
Incorporated in 1998, Indegene Ltd provides solutions consisting of analytics, technology and commercial, medical, regulatory and safety services to life science and health care organizations [1]
NSE INDGNBSE 544172
Health check
Constructive
ValuationFair
ProfitabilityAverage
GrowthHigh
TechnicalsBullish
52-week range
−3.67% from high₹589
₹424+39.13% from low₹612
Current
₹589.20
Prev close
₹598.00
Day
−1.47%
Price performance
1D
−1.47%
1W
−2.68%
1M
+3.60%
3M
+13.64%
6M
+27.42%
1Y
+7.91%
YTD
+12.75%
Financials
Revenue, profit & margin
P/E ratio
34.7×
INDGN is 3% below the sector median of 35.9×
INDGN34.7×
Sector median35.9×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 608 | 636 | 673 | 673 | 676 | 687 | 720 | 756 | 761 | 804 | 942 | 1,003 | 1,063 | |
| Expenses | 511 | 515 | 524 | 534 | 548 | 561 | 589 | 608 | 606 | 664 | 783 | 840 | 889 | |
| Operating Profit | 97 | 121 | 149 | 139 | 129 | 126 | 132 | 148 | 155 | 141 | 160 | 164 | 174 | |
| OPM % | 16% | 19% | 22% | 21% | 19% | 18% | 18% | 20% | 20% | 17% | 17% | 16% | 16% | |
| Other Income | 28 | 12 | 13 | 26 | 22 | 21 | 38 | 26 | 22 | 20 | 19 | -10 | 29 | |
| Interest | 13 | 12 | 12 | 12 | 12 | 4 | 3 | 3 | 4 | 4 | 5 | 7 | 6 | |
| Depreciation | 20 | 20 | 18 | 18 | 20 | 19 | 20 | 21 | 22 | 23 | 40 | 42 | 44 | |
| Profit before tax | 92 | 101 | 132 | 134 | 120 | 124 | 146 | 149 | 152 | 133 | 135 | 105 | 153 | |
| Tax % | 26% | 25% | 25% | 29% | 27% | 26% | 25% | 21% | 23% | 23% | 24% | 24% | 24% | |
| Net Profit | 68 | 75 | 99 | 95 | 88 | 92 | 110 | 118 | 116 | 102 | 103 | 80 | 116 | |
| EPS in Rs | 3.08 | 3.38 | 4.45 | 4.26 | 3.67 | 3.83 | 4.58 | 4.90 | 4.85 | 4.25 | 4.28 | 3.31 | 4.82 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +0.09% · closed higher next day 1 of last 1
| Q1FY27 | |
|---|---|
| Broadcast | 30 Jul '26◦ |
| Earnings day | +0.09% |
| +1 day | +5.94% |
| +5 days | +7.72% |
| +15 days | +10.32% |
| +30 days | — |
| Filing |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Results analysis
Shareholding
as of Jun 2026FIIs9.92%0.35
DIIs8.74%0.45
Public81.34%0.09
Ownership trend
Peers
7 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| SYNGENE | ₹389.30 | 53.06 | 15,715 | 0.32% | −9 | −94.89% | 736 | −15.84% | 9.99% |
| INDGN | ₹599.35 | 34.69 | 14,440 | 0.38% | 116 | −0.17% | 1,063 | +39.73% | 18.82% |
| SUVEN | ₹377.15 | — | 10,657 | 0.00% | −128 | −147.69% | 4 | +90.91% | −79.54% |
| VIMTALABS | ₹640.65 | 35.43 | 2,863 | 0.31% | 21 | +11.38% | 109 | +11.80% | 25.23% |
| FABTECH | ₹148.47 | 13.57 | 660 | 0.40% | 4 | +154.79% | 75 | +10.25% | 13.58% |
| BI | ₹100.64 | 11.91 | 237 | 0.00% | 15 | +473.06% | 226 | +21.20% | 5.56% |
| NOVELIX | ₹77.49 | 60.94 | 221 | 0.00% | 1 | +972.73% | 37 | +65.15% | 9.98% |
| Median: 9 Co. | ₹148.47 | 35.91 | 660 | 0.00% | 1 | +117.42% | 75 | +30.46% | 9.99% |
Filings
Concall transcripts31
TranscriptAug 2026PPTAug 2026RECAug 2026PPTMay 2026TranscriptMay 2026PPTMay 2026RECMay 2026PPTApr 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026TranscriptNov 2025PPTNov 2025TranscriptOct 2025PPTOct 2025RECOct 2025TranscriptAug 2025PPTAug 2025TranscriptMay 2025PPTMay 2025RECMay 2025PPTMar 2025TranscriptFeb 2025PPTFeb 2025
Announcements5
Announcement Under Regulation 30 (LODR) - Update On Material Litigation 31 Aug - US court preliminarily approved Indegene Inc.’s class-action settlement; final hearing set for 12 January 2027, max USD 4.72 million.Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 19 Aug - Indegene schedules investor meetings with MFS, ASK, Mirae on 24 Aug 2026; Goldman Sachs and Seven Canyon on 25 Aug 2026.Announcement Under Regulation 30 (LODR) - Update On Material Litigation 19 Aug - Indegene subsidiary nearing TCPA class-action settlement; maximum fund about USD 4.72 million, subject to court approval.Transcript Of The 28Th Annual General Meeting Held On August 13, 2026 17 AugAnnouncement under Regulation 30 (LODR)-Change in Directorate 17 Aug - Shareholders approved appointment of Ms. Jill Mary De Simone as Independent Director for 3 years from January 22, 2026.